Skip to main content
MedPathMedPath Home
Clinical Trials/TCTR20180115001
TCTR20180115001
Not yet recruiting
未知

Intra-ocular pressure reduction efficacy and safety of generic latanoprost marketed in Thailand after switching from the original: a randomized open-labelled controlled trial

Bausch & Lomb Co., Ltd.0 sites70 target enrollmentJanuary 15, 2018
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Bausch & Lomb Co., Ltd.
Enrollment
70
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 15, 2018
End Date
January 1, 2019
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Bausch & Lomb Co., Ltd.

Eligibility Criteria

Inclusion Criteria

  • •Patients who have been diagnosed with any type of glaucoma or ocular hypertension
  • •No history of cataract within the last 3 months
  • •Using the original latanoprost (Xalatan) for more than 4 weeks

Exclusion Criteria

  • •History of any type of intraocular pressure reduction surgery
  • •History of laser peripheral iridotomy within the last 3 months
  • •History of ocular trauma
  • •Currently on more than 1 antihypertensive eyedrops apart from latanoprost
  • •History of any irregular ocular surface condition
  • •Currently on glucocorticoid eyedrops

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Effect of pressure reducing effect of Ripasudil eye drops in patients with high pressure within the eyeHealth Condition 1: H401- Open-angle glaucoma
CTRI/2022/09/045191Sankara eye hospital
Completed
Not Applicable
Evaluation of the Intraocular pressure lowering effect of Tafluprost and Latanoprost on normal tension GlaucomaGlaucoma
JPRN-UMIN000002017Department of ophthalmology, Kyoto Prefectural University of Medicine30
Completed
Not Applicable
Comparison of intraocular pressure lowering effects among four prostaglandin analogues: parallel administration to the bilateral eyes of normal subjects.glaucoma, ocular hypertension
JPRN-UMIN000003810Department of Ophthalmology, Houju Memorial Hospital25
Completed
Not Applicable
A study of the intraocular pressure lowering effect of topical application of ripasudil in clinical practiceGlaucoma
JPRN-UMIN000025466Kobe University Graduate School of Medicine130
Completed
Phase 3
A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI StudyPrimary Open Angle Glaucoma or Ocular Hypertension
NCT02822742Santen Pharmaceutical Co., Ltd.26